GlassScriptPhysician profile
Madhurima Anne
NPI 1326287624
$3,470.79
in general payments reported to CMS, 2019-2025
51 companies · $1,185 in 2025
The $1,185 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $41.14 · 2021: $127 · 2022: $406 · 2023: $853 · 2024: $687 · 2025: $1,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Education: $22.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.23 |
| Education | $22.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $311.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.54 | 2019-2025 | Opdivo, Opdualag |
| Eisai INC. | $203.95 | 2022-2025 | |
| Stemline Therapeutics INC. | $203.27 | 2023-2025 | Orserdu |
| Gilead Sciences, INC. | $200.71 | 2023-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $178.10 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Taiho Oncology, INC. | $176.95 | 2024-2025 | |
| Abbvie INC. | $168.96 | 2020-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $158.03 | 2021-2025 | Evusheld, Brilinta, Tagrisso |
| Daiichi Sankyo INC. | $131.67 | 2022-2025 | Enhertu |
| Janssen Biotech, INC. | $118.84 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Genmab U.S., INC. | $110.18 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $81.37 | 2022-2024 | Libtayo |
| Pfizer INC. | $80.14 | 2024-2025 | |
| Springworks Therapeutics, INC. | $75.57 | 2024-2025 | Ogsiveo |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhurima Anne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.